E-course: From molecular environment to theranostics in hormone-sensitive prostate cancer

This e-course will present data from one of the biggest PCa biomarker repository platform in the world; unravel new potential radioligands for a finer characterisation of the disease; and also discuss the outlook of theranostic in hormone-sensitive setting.

Published Tue, 5 Mar 2024
E CourseProstate CancerOncologyHormone SensitivePCAEAU Section Of Urological ImagingEAU Section Of Urological Research
Organiser European School of Urology (ESU)
CME 1.00
Duration Approx. 70 minutes

Prostate cancer (PCa) is a heterogeneous neoplasm with different molecular signature profiles. Their identification is among the most difficult challenges in current research, but their clinical implications are broad. These encompass the discovery of new biomarkers in blood, urine or tissue samples, the expansion of radioligands for molecular imaging diagnosis and staging, and the development of targeted treatments including theranostic.

Ass. Prof. D. Oprea-Lager (NL)
Prof. K.A. Tasken (NO)
Prof. F. Sanguedolce (ES)
Dr. J. Lindberg (SE)
Dr. D. S. S. Scherr (US)

This e-course is brought to you in collaboration with ESUI and ESUR.

Contact our organiser

European School of Urology (ESU)

Email:  educationonline@uroweb.org